This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Aug;156(2):208-209.

doi: 10.1016/j.chest.2019.03.029.

Rebuttal From Dr Prasse

Affiliations

Affiliation

¹ Hannover Medical School and Deutsches Zentrum für Lungenforschung (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany. Electronic address: prasse.antje@mh-hannover.de.

PMID: 31395257
DOI: 10.1016/j.chest.2019.03.029

Editorial

Rebuttal From Dr Prasse

Antje Prasse. Chest. 2019 Aug.

. 2019 Aug;156(2):208-209.

doi: 10.1016/j.chest.2019.03.029.

Author

Affiliation

¹ Hannover Medical School and Deutsches Zentrum für Lungenforschung (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany. Electronic address: prasse.antje@mh-hannover.de.

PMID: 31395257
DOI: 10.1016/j.chest.2019.03.029

No abstract available

PubMed Disclaimer

Comment on

COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? No.
Ley B. Ley B. Chest. 2019 Aug;156(2):205-208. doi: 10.1016/j.chest.2019.03.027. Chest. 2019. PMID: 31395256 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information